New drugs under development for COPD.

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Respiratory Diseases

Background:

• Chronic obstructive pulmonary disease (COPD) is a progressive lung disease with increasing global prevalence.
• Current therapies for COPD are limited, failing to halt disease progression or address all key pathological features.
• The heterogeneous nature of COPD development complicates the creation of effective new treatments.

Purpose of the Study:

• To review advancements in existing COPD drug classes.
• To highlight novel therapeutic compounds targeting newly identified COPD mechanisms.
• To discuss future directions for personalized COPD treatment strategies.

Main Methods:

• Comprehensive literature review of existing and emerging COPD therapies.
• Analysis of drug classes including glucocorticoids, bronchodilators, and enzyme inhibitors.
• Exploration of novel agents targeting inflammation, fibrosis, and regeneration.

Main Results:

• Improvements in established drug classes like glucocorticoids and PDE inhibitors are discussed.
• Emerging therapies include dual-action muscarinic antagonists, kinase inhibitors, and senolytics.
• Novel approaches also encompass antioxidants, antivirals, anti-fibrotics, and lung regeneration stimulants.

Conclusions:

• Personalized treatment approaches considering COPD phenotypes/endotypes are crucial for future therapeutic success.
• A deep understanding of disease mechanisms in specific patient subsets will guide the appropriate targeting of novel therapies.
• The review provides a comprehensive overview of the therapeutic landscape for COPD, from established treatments to cutting-edge research.